



June 21, 2023
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Directors' Responsibilities Changes and Organizational and Personnel Changes

June 21, 2023 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") hereby announces that its Board of Directors resolved at a meeting held today to change directors' responsibilities and organizational and personnel changes as follows.

1. Directors' Responsibilities Changes, Organizational Changes (As of August 1, 2023)
 - (1) Directors' Responsibilities Changes
The Management Team composed of Directors, Senior Corporate Officers and some Corporate Officers will change some responsibilities for Directors as noted in the table below to further clarify areas of responsibility.

Name	New Area of Supervision	Current Area of Supervision
Mathias Schmidt, PD, Ph.D. (Vice President, ArmaGen, Inc. CEO JCR USA, Inc. President and CEO)	Clinical development (overall supervision) Business development and IR fields, excluding Japan	Clinical development

- (2) Restructure of Development Departments
JCR will reorganize the chain of command and restructure the organization to accelerate clinical development in Japan and globally.
The Domestic Development Unit and International Development Unit will be newly established within the Development Division.
The Domestic Clinical Operation Group, Data Science Group and Domestic Project Coordination Group will be newly established under the Domestic Development Unit, and the International Clinical Operation Group, Clinical Development Group and Project Management Office under the International Development Unit, and they will share carrying out the functions of existing development departments.
- (3) Organizational Affiliation Change of New Global Business Operations
The New Global Business Operations will be placed under the Corporate Strategy Division to strengthen collaboration with partners.

2. Change of Corporate Officer (As of July 1, 2023)

Name	New Title	Current Title
Junichi Ando	Corporate Officer Executive Director, Quality Assurance Division Director, Regulatory Affairs Department	Corporate Officer Executive Director, Quality Assurance Division

3. Personnel Changes (As of August 1, 2023)

Name	New Title	Current Title
Sairei So	Director, International Development Unit, Development Division	Director, International Project Unit
Tatsuyoshi Yamamoto	Director, Domestic Development Unit, Development Division	Director, Domestic Clinical Operation Promotion Unit Director, Domestic Project Unit Development Division
Masaaki Usui	Director, New Global Business Operations, Corporate Strategy Division	Director, New Global Business Operations

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 48-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products News Release in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS III A and B (Sanfilippo type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###